We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Visit expo >

New

Gold Member

Neonatal Heel Incision Device

Tenderfoot

New

Gold Member

STI Test

Vivalytic MG, MH, UP/UU

New

Automated Urinalysis Solution

UN-9000

New

Automated Clinical Chemistry Analyzer

Envoy 500+

Latest MEDICA 2022 News

Channels

Clinical Chemistry

view channel

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Image: ApoB is a blood test that counts the total number of harmful particles in circulation, providing a more complete assessment of risk (photo courtesy of Adobe Stock)

Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy

Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more

Molecular Diagnostics

view channel

Image: Graphical abstract (Huang, A. Y. et al., Cell (2026). DOI: 10.1016/j.cell.2026.03.040)

Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s

Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more

Composite Blood Biomarkers Enable Early Detection of Common Cancers

Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more

Image: Graphical abstract (Robinson S, Haile B, Reily-Bell M et al, Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.102744)

Blood Test Enables Early Detection and Classification of Glioma

High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more

Hematology

view channel

Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching

CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more

Image: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior (photo courtesy of Shutterstock)

Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more

Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality

Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more

Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer

Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more

Immunology

view channel

Image: Graphical abstract - Human immune aging clock identifies RUNX1 as a decelerator of T cell senescence (photo courtesy of Zhang Weiqi)

Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target

Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more

Study Finds Influenza Often Undiagnosed in Winter Deaths

Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more

Combined Screening Approach Identifies Early Leprosy Cases

Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more

Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Microbiology

view channel

Image: Graphical abstract (Qin, Y. et al., Cell Rep Med 7: 102761 (2026). DOI: 10.1016/j.xcrm.2026.102761)

Oral–Gut Microbiome Signatures Identify Early Gastric Cancer

Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more

Image: Magnetic field-enhanced alignment and detection of hemozoin in lysed infected red blood cells using polarizing microscopy (photo courtesy of Dickson Mwenda Kinyua, Kirinyaga University)

Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria

Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more

Gut Microbiome Test Predicts Melanoma Recurrence After Surgery

Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more

Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections

Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read more

Pathology

view channel

Image: The PRET system provides an integrated solution for multiple pathology diagnostic tasks, including cancer screening, tumor subtyping, tumor segmentation, and lymph node metastasis detection (Li, Y., Ning, Z., Xiang, T. et al. Nature Cancer (2026). doi.org/10.1038/s43018-026-01141-2)

Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides

Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more

Image: Artera’s multi-modal AI platform analyzes digital pathology and clinical data to support personalized cancer management (photo courtesy of Artera)

AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer

Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read more

Image: The model analyzes routinely collected pathology slides to detect complex tissue features associated with immunotherapy response in metastatic NSCLC (photo courtesy of Shutterstock)

AI Pathology Model Predicts Immunotherapy Response in Lung Cancer

Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more

AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides

Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more

Technology

view channel

AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer

Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more

Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing

Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more

Noninvasive Sputum Test Detects Early Lung Cancer

Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more

Image: Graphical Abstract (Huiqian Hu et al., Med 7(3): 100966 (2026). DOI: 10.1016/j.medj.2025.100966)

New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia

Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more

Industry

view channel

Image: The acquisition adds the LEX VELO System to QuidelOrtho’s portfolio (photo courtesy of LEX Diagnostics)

QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition

QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more

Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID

Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more